Creative Touch Permanent Makeup and Aesthetics

Oestrogen decline is not a single skin ageing mechanism, it is three concurrent ones. Falling oestrogen reduces collagen synthesis whilst elevating MMP-driven degradation, directly impairs ceramide production in the stratum corneum (measurable as shorter chain lengths and higher transepidermal water loss), and degrades the ECM environment that fibroblasts need to remain functional. These changes operate through systemic oestrogen loss, declining local skin production, and reduced receptor expression simultaneously. Treating any one mechanism whilst leaving the others unaddressed produces incomplete results. The most effective protocols work across all three.

Oestrogen decline refers to the gradual but accelerating reduction in circulating oestrogen – primarily 17β-oestradiol – that begins during perimenopause and culminates in the complete cessation of ovarian oestrogen production after menopause. Because the skin functions as an endocrine organ, with keratinocytes and fibroblasts both producing and responding to oestrogen, this hormonal shift affects every structural layer of the skin simultaneously. The result is not simply “skin ageing” but a distinct biological process, driven by hormonal change rather than chronological time, that operates faster and through mechanisms that differ meaningfully from the ageing that affects men over the same period.

Three Mechanisms, One Transition

What makes oestrogen decline clinically significant is that it drives skin changes through three concurrent and compounding mechanisms rather than one. A 2025 narrative review in the Journal of Cosmetic Dermatology (Viscomi et al.) characterised these as: reduced systemic oestrogen from diminished ovarian synthesis; declining local oestrogen production within the skin itself; and reduced expression of oestrogen receptors in cutaneous tissue. ^[3]

This distinction matters. After menopause, peripheral tissues (including skin) attempt to compensate by converting DHEA into oestradiol and oestrone via aromatase activity. But DHEA levels also decline with age, progressively reducing this compensatory capacity. The skin therefore faces not just a falling oestrogen supply but a declining ability to produce or even receive oestrogen locally. The hormone isn’t simply less available; the machinery for using it is also winding down. ^[3]

What Oestrogen Was Actually Doing

Understanding what oestrogen decline takes away requires being specific about what oestrogen was providing. In the dermis, oestrogen supports fibroblast function through both genomic (oestrogen receptor-mediated) and non-genomic pathways. The non-genomic route operates through GPR30, a G protein-coupled receptor that triggers rapid ERK1/2 activation – influencing fibroblast cytoskeletal organisation, focal adhesion density, and cell morphology in ways that are entirely independent of classical oestrogen receptor signalling. ^[1] When oestrogen is withdrawn from isolated human dermal fibroblasts in primary culture, the cytoskeleton reorganises, focal adhesion numbers drop substantially, and cell shape changes; all reversible by 17β-oestradiol reintroduction. A fibroblast that has lost oestrogen signalling is a structurally different, functionally compromised cell before any other ageing mechanism has touched it.

In the epidermis, oestrogen directly influences ceramide production. A 2022 lipidomic study in Scientific Reports (Teng et al.) measured stratum corneum ceramides in pre-menopausal, post-menopausal, and HRT-using women and found that post-menopausal skin showed both reduced ceramide abundance and shorter ceramide chain lengths – shorter ceramides forming a less effective lamellar matrix and correlating directly with higher transepidermal water loss (TEWL). Serum oestradiol correlated positively with both ceramide abundance and chain length. Primary keratinocyte culture confirmed the causal relationship: oestradiol treatment directly increased CER[NS] and CER[NDS] ceramide production. ^[2] The ceramide shortfall in menopausal skin is not incidental to oestrogen loss, it is a direct consequence of it.

Oestrogen also stimulates hyaluronic acid (HA) synthesis in the dermis through its influence on glycosaminoglycan production, and maintains sebum production through sebaceous gland activity. Declining oestrogen removes these inputs simultaneously, reducing both the deep hydration reserve and the surface lipid layer that limits transepidermal water loss. ^[3]

The Collagen Picture Is More Precise Than “30% Loss”

The commonly cited statistic – 30% collagen loss in the first five years after menopause – is real, but it understates how specifically this happens. Research by Brincat et al. found that skin collagen content declines at approximately 2.1% per postmenopausal year over a 15-year period, and that this decline correlates with menopausal age rather than chronological age. ^[3] The distinction is important: matched for chronological age, women post-menopause lose collagen faster than pre-menopausal women of the same age. Hormonal status, not time, is the operative variable.

Both Type I collagen (structural strength) and Type III collagen (elastic responsiveness) decline, but they do not decline equally. As established in the Collagen entity, the Type I:III ratio shifts as Type III is disproportionately reduced, and since hybrid I/III fibrils are more effective at stimulating fibroblast activity than either type alone, the compositional change feeds back into further impaired synthesis. The ECM weakening that follows accelerates fibroblast senescence, and senescent fibroblasts secrete matrix-degrading enzymes and pro-inflammatory cytokines, creating a self-reinforcing loop that amplifies the structural decline from within. ^[3]

The problem is not that fibroblasts stop trying. It is that the environment in which they operate progressively deteriorates, making what they produce less effective and shorter-lived.

Epidermal Thinning and Barrier Vulnerability

The epidermis also thins post-menopause at approximately 1.13% skin thickness reduction per year (as established in the Epidermis entity, sourced from the same Brincat cohort data). Reduced oestrogen decreases keratinocyte proliferation, producing a thinner, more slowly renewing epidermal population. As the epidermis thins, the stratum corneum paradoxically thickens, reflecting disrupted epidermal homeostasis rather than improved protection. ^[3]

Simultaneously, CD44 expression – the receptor through which hyaluronic acid signals into basal keratinocytes – decreases post-menopause, reducing the HA signalling that normally supports epidermal renewal and structural coherence. The barrier becomes thinner, drier, and more slowly repaired at the same time. Each layer is affected by the same hormonal shift, and the effects compound across layers rather than occurring in isolation.

Why the Trajectory Matters for Treatment Timing

Skin elasticity declines at approximately 1.5% per year post-menopause, with distensibility increasing and structural rigidity declining simultaneously. ^[3] The research framing from the menopausal procollagen paradox (established in the Collagen entity) applies directly here: post-menopausal fibroblasts can increase procollagen gene expression as a compensatory response, yet produce less functional collagen because of impaired hydroxylation, elevated MMP activity, and deteriorating ECM support. Treatments that only address the synthesis side of this equation, without addressing the MMP degradation environment, the ECM mechanosensing context, or the ceramide-barrier stability, are working on a step that the body is already partly compensating for.

This is not a pessimistic framing. It is the basis for a more precise treatment approach. The biology of oestrogen decline is well enough characterised to map specifically onto the treatments most capable of addressing what is actually failing, rather than applying generic skin rejuvenation protocols to a hormonally distinct skin environment.